Press release
The market for non-small cell lung cancer (NSCLC) is expected to reach USD 79.1 billion by 2034, propelled by industry titans like Bristol Myers-Squibb and Roche.
Non-Small Cell Lung Cancer
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72857
The global NSCLC market continues to grow rapidly, driven by rising incidence, increased smoking prevalence in developing countries, and advances in precision medicine, biomarker-driven therapies, and next-generation immunotherapies. With strong clinical pipelines, expanding indications, and personalized medicine approaches, the NSCLC market is expected to remain one of the largest oncology markets worldwide.
Market Overview
• Market Size 2024: USD 28.4 billion
• Forecast 2034: USD 79.1 billion
• CAGR (2024-2034): 10.9%
Key Highlights:
• Targeted therapies (EGFR, ALK, ROS1, KRAS inhibitors) dominate the precision medicine landscape.
• Immunotherapies (PD-1, PD-L1, and CTLA-4 inhibitors) are transforming treatment across multiple stages of NSCLC.
• Rising prevalence of lung cancer due to tobacco use, air pollution, and occupational exposure fuels demand.
• North America and Europe remain dominant, while Asia-Pacific emerges as the fastest-growing hub.
Challenges include therapy resistance, high treatment costs, and disparities in access across low-income regions. Still, innovation ensures continued expansion.
Market Segmentation
By Histology
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma
By Therapy Type
• Chemotherapy
• Targeted Therapy (EGFR, ALK, ROS1, KRAS, Others)
• Immunotherapy (PD-1, PD-L1, CTLA-4 Inhibitors)
• Combination Therapies
• Radiation Therapy
• Surgery
By Biomarker Status
• EGFR Mutation Positive
• ALK Rearrangement Positive
• ROS1 Positive
• KRAS Mutation Positive
• PD-L1 High Expression
• Others
By End User
• Hospitals
• Specialty Cancer Centers
• Academic & Research Institutes
Segmentation Summary:
Targeted therapy and immunotherapy are the fastest-growing segments, particularly for patients with actionable mutations or high PD-L1 expression. Adenocarcinoma remains the most common histology, while combination therapies are increasingly used to overcome resistance. Hospitals and specialty oncology centers dominate as end users.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72857/non-small-cell-lung-cancer-market
Regional Analysis
North America
• Largest market with ~45% share in 2024.
• Driven by advanced diagnostics, high adoption of immunotherapies, and strong presence of pharma giants.
• The U.S. dominates with FDA approvals of multiple targeted and immunotherapy drugs.
Europe
• Significant market share, ~30%.
• EMA approvals and inclusion of targeted therapies in treatment guidelines fuel growth.
• Germany, France, and the UK are key contributors.
Asia-Pacific
• Fastest-growing region, CAGR above 12%.
• High prevalence of smoking-related NSCLC in China and India.
• Expanding clinical trial activity and improving access to biomarker testing.
Middle East & Africa
• Early adoption stage, but lung cancer burden is increasing due to smoking and pollution.
• Limited access to advanced therapies remains a challenge.
Latin America
• Brazil and Mexico lead, supported by strengthening cancer treatment infrastructure.
• Growth moderate compared to APAC, but improving with rising healthcare investment.
Regional Summary:
North America and Europe dominate today, but Asia-Pacific is expected to be the fastest-growing market by 2034, reshaping the global NSCLC treatment landscape.
Market Dynamics
Growth Drivers
• Rising Lung Cancer Prevalence: Increasing tobacco use and environmental pollution.
• Precision Medicine Expansion: Targeted therapies for EGFR, ALK, KRAS, and ROS1 mutations.
• Immunotherapy Adoption: Checkpoint inhibitors improving outcomes across lines of therapy.
• Government & NGO Initiatives: Awareness campaigns and screening programs supporting early detection.
Key Challenges
• Drug Resistance: Patients often relapse despite targeted or immunotherapy.
• High Therapy Costs: Advanced biologics and targeted drugs remain unaffordable for many.
• Access Gaps: Limited biomarker testing and therapy availability in developing nations.
• Regulatory Hurdles: Complex approval pathways for combination regimens.
Latest Trends
• Next-gen Immunotherapies: Novel checkpoint inhibitors and CAR-T therapies under investigation.
• Liquid Biopsies: Improving real-time monitoring of mutations and resistance.
• Combination Approaches: Targeted + immunotherapy or chemo-immunotherapy combinations.
• Expanded Biomarker Use: Precision therapy guided by multi-gene profiling.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72857
Competitive Landscape
Key Players
• F. Hoffmann-La Roche Ltd. (Tecentriq, Avastin, Tarceva)
• Bristol Myers Squibb (Opdivo, Yervoy)
• Merck & Co., Inc. (Keytruda)
• AstraZeneca plc (Tagrisso, Imfinzi)
• Novartis AG
• Pfizer Inc. (Lorbrena, Vizimpro)
• Amgen Inc. (Lumakras - KRAS G12C inhibitor)
• Eli Lilly and Company
• Takeda Pharmaceutical Company (Alunbrig)
• Johnson & Johnson (Janssen Biotech)
• Boehringer Ingelheim International GmbH
• BeiGene Ltd.
• Zai Lab Ltd.
• Innovent Biologics, Inc.
• Regeneron Pharmaceuticals, Inc.
Competitive Summary:
The NSCLC market is highly competitive, with global giants like Roche, BMS, Merck, and AstraZeneca leading with immunotherapies and targeted drugs. Emerging players such as Amgen (KRAS inhibitors) and Chinese biotech firms (BeiGene, Zai Lab, Innovent) are reshaping competition. Partnerships, acquisitions, and tumor-agnostic drug trials are defining market dynamics.
Conclusion
The Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow from USD 28.4 billion in 2024 to USD 79.1 billion by 2034, at a CAGR of 10.9%. Rising lung cancer incidence, expanding biomarker-driven precision medicine, and growing adoption of immunotherapies are driving robust growth.
North America and Europe dominate today, but Asia-Pacific will be the fastest-growing region, driven by its large patient pool, high smoking prevalence, and expanding access to advanced therapies.
With breakthroughs in next-gen immunotherapies, liquid biopsies, and combination regimens, the NSCLC market is positioned for continued transformation. For pharma innovators, diagnostic firms, and healthcare investors, NSCLC remains one of the most promising and competitive oncology markets globally.
This report is also available in the following languages : Japanese (非小細胞肺がん), Korean (비소세포폐암), Chinese (非小细胞肺癌), French (cancer du poumon non à petites cellules), German (Nicht-kleinzelliger Lungenkrebs), and Italian (Carcinoma polmonare non a piccole cellule), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72857/non-small-cell-lung-cancer-market#request-a-sample
Our More Reports:
Glycated Haemoglobin Testing Market
https://exactitudeconsultancy.com/reports/73489/glycated-haemoglobin-testing-market
Single Use Mixer Market
https://exactitudeconsultancy.com/reports/73490/single-use-mixer-market
PFAS Testing Market
https://exactitudeconsultancy.com/reports/73491/pfas-testing-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The market for non-small cell lung cancer (NSCLC) is expected to reach USD 79.1 billion by 2034, propelled by industry titans like Bristol Myers-Squibb and Roche. here
News-ID: 4204178 • Views: …
More Releases from Exactitude Consultancy
Vacuum Insulated Pipe Market Projected to Reach USD 2.36 Billion by 2034
Introduction: A Market Built on Cryogenic Efficiency and Innovation
The global Vacuum Insulated Pipe (VIP) market is witnessing a steady surge driven by the expanding cryogenic industry, increased liquefied natural gas (LNG) trade, and rising demand for efficient liquid gas transportation systems. These specialized double-wall pipes, engineered with high vacuum insulation between inner and outer layers, have become indispensable in industries handling cryogenic fluids such as liquid nitrogen, oxygen, argon, and…
Solar PV Mounting Systems Market is Expected to Reach USD 31.7 Billion by 2034
Introduction: Powering the Next Decade of Solar Expansion
The Solar PV Mounting Systems Market is emerging as a crucial pillar in the clean energy revolution, enabling efficient, cost-effective, and durable installations of photovoltaic (PV) modules across rooftops, open fields, and floating structures. As the world accelerates toward carbon neutrality, the demand for robust, modular, and adaptable mounting systems has intensified across residential, commercial, and utility-scale solar projects.
Download Full PDF Sample Copy…
Tall Oil Fatty Acid Market projected to reach USD 2.21 billion by 2034
Introduction: A Sustainable Feedstock Powering the Future of Bio-based Chemicals
The Tall Oil Fatty Acid (TOFA) Market is gaining strong traction as industries increasingly shift toward renewable, sustainable, and bio-based chemical alternatives. Derived as a byproduct from the kraft pulping process of pine wood, TOFA has become a vital raw material in the production of alkyd resins, dimer acids, lubricants, coatings, and adhesives. Its unique composition-rich in oleic and linoleic acids-makes…
Lithium-Ion Battery Recycling Market Projected to Reach USD 27.3 Billion by 2034
Introduction: Powering the Circular Energy Transition
As the world accelerates toward electrification and clean energy, the demand for lithium-ion batteries has skyrocketed-fueling everything from electric vehicles (EVs) to smartphones and grid storage systems. However, this exponential growth brings with it an urgent environmental challenge: how to sustainably manage end-of-life batteries.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/25354
The Lithium-Ion Battery Recycling Market has emerged as a cornerstone of the global…
More Releases for NSCLC
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
